Cargando…

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extensio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costabel, Ulrich, Albera, Carlo, Glassberg, Marilyn K., Lancaster, Lisa H., Wuyts, Wim A., Petzinger, Ute, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Noble, Paul W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416878/ https://www.ncbi.nlm.nih.gov/pubmed/30866942 http://dx.doi.org/10.1186/s12931-019-1021-2

Ejemplares similares

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
por: Noble, Paul W., et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
por: Lancaster, Lisa H., et al.
Publicado: (2020)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
por: Gotfried, Mark H., et al.
Publicado: (2018)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
por: Wuyts, Wim A., et al.
Publicado: (2022)

The changing treatment landscape in idiopathic pulmonary fibrosis
por: Costabel, Ulrich
Publicado: (2015)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
por: Alhamad, Esam H.
Publicado: (2015)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
por: Lyseng-Williamson, Katherine A.
Publicado: (2017)

Pirfenidone-Induced Photosensitivity in a Patient with Idiopathic Pulmonary Fibrosis
por: Kim, Ho-Jin, et al.
Publicado: (2018)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
por: Kubbara, Aahd, et al.
Publicado: (2023)

Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program
por: Lancaster, Lisa, et al.
Publicado: (2017)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nmqkl4ctpqa3tabqi43p0aber7